Newly published data suggests most patients are opting for second- or third-generation tyrosine kinase inhibitors instead of a generic form of imatinib. Patients with chronic myelogenous leukemia (CML ...

The life expectancy of patients with recently diagnosed chronic myeloid leukemia (CML) is now approaching that of the general population, which is an important message for physicians to convey to ...

An advocate discusses vital patient-provider conversations to promote the best care for individuals with chronic myeloid leukemia. Receiving a diagnosis of chronic myeloid leukemia (CML) can be ...

MSD’s acquisition of Terns Pharmaceuticals is a calculated, forward-looking manoeuvre to secure the next generation of ...

A very unusual case of 2 chronic leukemias, chronic lymphocytic leukemia (CLL) and secondary chronic myeloid leukemia (CML) existing simultaneously in an older patient was treated with a pair of ...

Enliven's ELVN-001 is a high-potential investigational therapy with a best-in-class profile, offering a complementary mechanism to the approaches of Novartis’s Asciminib and TERN-701, the analyst said ...

Chronic myeloid leukemia (CML) is highly treatable. With an experienced care team, most people do well for many years on medicines they take at home. At Fred Hutch Cancer Center, our CML experts ...

LONDON--(BUSINESS WIRE)--The global chronic myelogenous leukemia (CML) therapeutics market size is poised to grow by USD 1.74 billion during 2019-2023, according to a new report by Technavio, ...

With today’s medicines, most people with chronic myeloid leukemia (CML) have a normal lifespan and a good quality of life. The key is to get care from CML experts — like the physicians at Fred ...